Peptides and Heparin Market Analysis and Research to Witness Relatively Significant Growth During 2017 to 2026

According to Fact.MR, the global peptide and heparin market is projected to reflect a high single-digit CAGR throughout the forecast period (2017-2026). The peptide and heparin market is estimated to reach nearly US$ 35,000 Mn revenues by 2026-end.

Vendors of Peptide Therapeutics are Outsourcing Manufacturing Processes to Developing Countries

Although therapeutic peptides were originally developed for replacing their endogenous lack, spectrum of the candidate peptide drugs available is not by far restrained to human peptide pool. With the help of multifarious organisms, bioactive peptides are being discovered through modern tools of peptidomics. A virtually infinite range of potential peptide-based medications await pharmacological characterization. Meanwhile, several methods of peptide synthesis are evolving to enable highly efficient production of extraordinarily long & heavily-modified compounds. Numerous clinical trials associated with peptide drug candidates are currently being conducted, which in turn represents a bright future for peptide-based therapeutics. Vendors of peptide therapeutics have been moving to developing countries on the back of large population base serving as potential clinical subjects. Lenient regulatory guidelines, skilled labor, low manufacturing costs, and low market competition are primary reasons why vendors of peptide therapeutics are outsourcing their manufacturing processes to these countries.

The quashing of bovine heparin by the FDA was majorly attributed to the concern with respect to adulteration. Having said that, on the back of acute shortage of procine heparin, FDA has started to encourage bovine heparin manufacturers to reintroduce their product, which in turn has resulted in the surge of amount of crude heparin.

Get Free Sample Report Here: https://www.factmr.com/connectus/sample?flag=S&rep_id=378

New oral anticoagulants being efficacious and safe is witnessing a rising demand in Asia-Pacific excluding Japan (APEJ). Against the backdrop of side effect with respect to heparin products—complications of bleeding and thrombocytopenia—the adoption of oral anticoagulants has expanded. Nevertheless, development in peptides synthesis technology coupled with soaring demand for peptides therapies in APEJ is anticipated to fuel the growth in the region.

Peptides and Heparin Market: Overview

The report provides a robust analysis on the market for peptides and heparin for the assessment period 2018-2026. The report peruses into the dynamics surrounding the peptides and heparin which significantly impact the growth of the market.

Furthermore, the report discerns the segregation of the market which is anticipated to provide readers with an actionable insights which will aid them in taking proper decision based on segments historical and future growth estimates.

The report focuses on cost structure and supply chain to provide a comprehensive view of the peptides and heparin market. The report also includes disease epidemiology and technology roadmap along with product lifecycle. Further, PESTLE analysis gives overall picture of the peptides and heparin market. The report provides a coherent assessment through average pricing analysis. The report also includes regional and country-wise assessment.

A qualitative and quantitative information has been obtained for the forecast and assessment on the peptides and heparin market. The research sources include primary and secondary sources which have been further examined by in-house panel of experts. The growth of end use industries in the historical and forecast period have been estimated to aid the readers with their business investment decisions. The market size of the peptides and heparin is the result of revenue comparison, market share comparison and Y-o-Y growth comparison on the geography.

Key Research Findings from Fact.MR’s Report on Peptide and Heparin Market

  • Oral route of administration will remain preferred for peptide and heparin
  • Cancer will continue to be the dominant indication segment in the market, in terms of revenues
  • Hospital pharmacies will remain the most lucrative distribution channel for peptide and heparin

Competition Tracking

The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.

Have Any Query?? Ask Our Industry Expert: https://www.factmr.com/connectus/sample?flag=AE&rep_id=378

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

sales@factmr.com

www.factmr.com

 

 

 

Matched content

Editor’s pick